Compare IZEA & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IZEA | IXHL |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Advertising | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.8M | 97.6M |
| IPO Year | 2010 | 2024 |
| Metric | IZEA | IXHL |
|---|---|---|
| Price | $3.69 | $3.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 62.5K | ★ 6.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $20,099,695.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.91 | N/A |
| P/E Ratio | $51.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.68 | $0.11 |
| 52 Week High | $5.86 | $5.17 |
| Indicator | IZEA | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 89.14 |
| Support Level | $3.48 | $0.32 |
| Resistance Level | $3.85 | N/A |
| Average True Range (ATR) | 0.20 | 0.13 |
| MACD | 0.06 | 0.39 |
| Stochastic Oscillator | 81.13 | 76.27 |
IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.